495 related articles for article (PubMed ID: 38339274)
21. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Liu L; Dong X
PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor mutations for precision medicine in prostate cancer.
Shiota M; Akamatsu S; Tsukahara S; Nagakawa S; Matsumoto T; Eto M
Endocr Relat Cancer; 2022 Oct; 29(10):R143-R155. PubMed ID: 35900853
[TBL] [Abstract][Full Text] [Related]
23. Molecular Origin, Expression Regulation, and Biological Function of Androgen Receptor Splicing Variant 7 in Prostate Cancer.
Chen Y; Lan T
Urol Int; 2021; 105(5-6):337-353. PubMed ID: 32957106
[TBL] [Abstract][Full Text] [Related]
24. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
25. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
[TBL] [Abstract][Full Text] [Related]
26. The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer.
Agarwal N; Zhang T; Efstathiou E; Sayegh N; Engelsberg A; Saad F; Fizazi K
Eur J Cancer; 2023 Oct; 192():113249. PubMed ID: 37672815
[TBL] [Abstract][Full Text] [Related]
27. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
28. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
Cai Z; Chen W; Zhang J; Li H
Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923
[TBL] [Abstract][Full Text] [Related]
29. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer.
Mohler ML; Sikdar A; Ponnusamy S; Hwang DJ; He Y; Miller DD; Narayanan R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672769
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Approaches to Targeting Androgen Receptor Splice Variants.
Daniels VA; Luo J; Paller CJ; Kanayama M
Cells; 2024 Jan; 13(1):. PubMed ID: 38201308
[TBL] [Abstract][Full Text] [Related]
31. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q
Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197
[TBL] [Abstract][Full Text] [Related]
32. The molecular underpinnings of prostate cancer: impacts on management and pathology practice.
Rodrigues DN; Boysen G; Sumanasuriya S; Seed G; Marzo AM; de Bono J
J Pathol; 2017 Jan; 241(2):173-182. PubMed ID: 27753448
[TBL] [Abstract][Full Text] [Related]
33. ncRNA-mediated overexpression of ubiquitin-specific proteinase 13 contributes to the progression of prostate cancer via modulating AR signaling, DNA damage repair and immune infiltration.
Cui X; Yu H; Yao J; Li J; Li Z; Jiang Z
BMC Cancer; 2022 Dec; 22(1):1350. PubMed ID: 36564767
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
Pilling A; Kim SH; Hwang C
Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379
[TBL] [Abstract][Full Text] [Related]
35. A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling.
Köhler A; Demir U; Kickstein E; Krauss S; Aigner J; Aranda-Orgillés B; Karagiannidis AI; Achmüller C; Bu H; Wunderlich A; Schweiger MR; Schaefer G; Schweiger S; Klocker H; Schneider R
Mol Cancer; 2014 Jun; 13():146. PubMed ID: 24913494
[TBL] [Abstract][Full Text] [Related]
36. Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies.
Labriola MK; Atiq S; Hirshman N; Bitting RL
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):301-309. PubMed ID: 33168966
[TBL] [Abstract][Full Text] [Related]
37. Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities.
Yu EM; Hwang MW; Aragon-Ching JB
Res Rep Urol; 2023; 15():519-529. PubMed ID: 38050587
[TBL] [Abstract][Full Text] [Related]
38. Efficient Everolimus Treatment for Metastatic Castration Resistant Prostate Cancer with
Yu Z; Wei W; Liu H; Pan E; Yang P; Jiang K
Onco Targets Ther; 2021; 14():5423-5428. PubMed ID: 34916807
[TBL] [Abstract][Full Text] [Related]
39. Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications.
Aurilio G; Cimadamore A; Mazzucchelli R; Lopez-Beltran A; Verri E; Scarpelli M; Massari F; Cheng L; Santoni M; Montironi R
Cells; 2020 Dec; 9(12):. PubMed ID: 33321757
[TBL] [Abstract][Full Text] [Related]
40. The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.
Huang KC; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
Cancer Biol Ther; 2014 Sep; 15(9):1120-8. PubMed ID: 24972028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
